StreetAlpha.app
Home › Stocks › SION

Sionna Therapeutics, Inc. (SION)

Healthcare
$2.83
▼ −4.88%
LAST CLOSE · NOV 20

Sionna Therapeutics develops experimental medicines for cystic fibrosis, a genetic disease that affects the lungs and other organs. It last closed at $2.83 on Nov 20, down 4.88% on the day. The next earnings report for SION is expected around Mon, Mar 1, 2027. For the quarter ended Sep 2026, SION reported EPS of -$0.72. Over its last 8 reports the stock moved an average of 5.8% the session after earnings. Over the last 12 months SION insiders bought $0 of stock on the open market and sold $145.6M, according to SEC Form 4 filings.

AI Auto Pilots
Is SION in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SION.

Key Stats

Last 12 months
Results
Net income
−$109.5M
EPS (diluted)
−$2.43
Free cash flow
−$79.6M
Valuation
Market cap
$127.8M
45.2M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$83.9M
At Sep 30
Shareholder equity
$240.5M
Shares outstanding
45.2M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: −$61.7M−$61.7MFY2024FY2025: −$75.3M−$75.3MFY2025

From SION's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 1
Estimated date · Time not announced
Reported EPS
-$0.72
Quarter ended Sep 2026
Year ago EPS
-$0.46
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$3.18Dec '24Mar 2025: -$0.62Mar '25Jun 2025: -$0.41Jun '25Sep 2025: -$0.46Sep '25Dec 2025: -$0.45Dec '25Mar 2026: -$0.60Mar '26Jun 2026: -$0.66Jun '26Sep 2026: -$0.72Sep '26Latest -$0.72
Revenue by quarter
Not enough quarters on file yet.
How SION moved after its last 8 reports
Average move the session after a report ±5.8%
Nov 10, 2026Time not announced+3.6%
Aug 6, 2026Time not announced+4.8%
May 12, 2026Time not announced−10.9%
Mar 2, 2026Time not announced−7.2%
Nov 5, 2025Time not announced−1.6%
Aug 11, 2025Time not announced+13.4%
May 12, 2025Time not announced+4.7%
Mar 20, 2025Time not announced0.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SIONStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SION
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SION

Technical Analysis

SION · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 24% below its 20 day and 58% below its 50 day average. It is 865% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the 52 week low at $2.75, and the nearest resistance the Pivot at $2.88.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.1%/day
Key levels
$54.9752 week high+1842.4%
$27.26200 day average+863.3%
$15.73100 day average+455.8%
$4.4750 day average+58.0%
$3.85Swing high (Nov 11)+36.0%
$3.4920 day average+23.3%
$3.01Pivot R1+6.4%
$2.88Pivot+1.8%
$2.83Last close
$2.7552 week low−2.8%
$2.70Pivot S1−4.6%
Indicators
RSI (14)25.85Oversold below 30Oversold
MACD-0.54Above its signal lineBullish
Stochastic7.0Near the bottom of its rangeOversold
ADX (14)40.1Strong downtrend
Williams %R-93.6Oversold below −80, overbought above −20Oversold
CCI (20)-147.4Oversold below −100, overbought above 100Oversold
Rate of change−13.9%Change over 10 sessionsBearish
ATR (14)$0.34Typical daily range, 12.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SION

What happened before

See how SION did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for SIONHow many large options trades hit SION, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SION Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲95 buying vs 79 selling
  • ▼Held by funds -6.0 pts
  • ▼Funds holding -11
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding136147−7.5%
In funds' top 1026−66.7%
Held by funds100.8%106.7%−6.0 pts
New / increased45 / 5034 / 57+4.4%
Reduced / sold out25 / 5440 / 8+64.6%
Put/call ratio0.976.74−85.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SION institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SION Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$145.6M26 sales · 7 insiders
77% of the selling was under pre-arranged trading plans.
2025-12 sold $3.6M2026-01 sold $10.0M2026-02 sold $2.8M2026-03 sold $347K2026-04 sold $50.8M2026-05 sold $26.7M2026-06 sold $10.5M2026-07 sold $8.2M2026-09 sold $21.8MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 17Ra Capital Management, L.P.DirectorSale3,448,811$6.33$21.8M
Jul 7Orbimed Advisors LLCDirectorSale plan85,918$44.86$3.9M
Jul 7Peter A. ThompsonDirectorSale plan85,918$44.86$3.9M
Jul 6Jennifer FitzpatrickChief Legal OfficerSale plan10,250$43.60$447K
Jun 30Orbimed Advisors LLCDirectorSale plan115,844$45.50$5.3M
Jun 30Peter A. ThompsonDirectorSale plan115,844$45.50$5.3M
Every insider buy and sale for SION over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SION insider trades →

From SEC Form 4 filings by SION's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SION is in one of them and how their past SION trades turned out.

SION in the AI portfolios
Loading…

SION News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SION in an article yet. Here's the latest on the wider market.

SION in the news

About Sionna Therapeutics

Sionna Therapeutics is a drug developer based in Waltham, Massachusetts. It is developing medicines for people with cystic fibrosis, an inherited disease that causes thick mucus to build up in the lungs, pancreas and other organs. Its candidates are designed to stabilize a part of the CFTR protein called NBD1, which is affected by the most common cystic fibrosis mutation. The company is still testing these candidates in clinical trials.

Headquarters
Waltham, MA